HIF1A and PDIA3 were highlighted as significant potential biomarkers, providing valuable insights into the molecular mechanisms of palmitoylation in OSA and potential therapeutic targets. This evidence concerns the gene PDIA3 and obstructive sleep apnea syndrome.